This site is intended for health professionals only

Amgen acquires heart-drug rights


UK biotech company Amgen is acquiring the rights to Cytokinetics’s experimental heart drug CK-1827452 at present being trialled for the treatment of heart failure.

Amgen will pay $50 million (£31.6m) upfront and up to $600 million in the future, depending on the drug’s success. CK-1827452 is a novel, small-molecule, direct activator of cardiac myosin, the motor protein that causes cardiac contraction.

Amgen had earlier paid $75m for the option to the drug, and decided to exercise the option after seeing more clinical data, according to the New York Times.

Copyright Press Association 2009


Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine